Mission Statement, Vision, & Core Values (2024) of Cabaletta Bio, Inc. (CABA)

Mission Statement, Vision, & Core Values (2024) of Cabaletta Bio, Inc. (CABA)

US | Healthcare | Biotechnology | NASDAQ

Cabaletta Bio, Inc. (CABA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Cabaletta Bio, Inc. (CABA)

General Summary of Cabaletta Bio, Inc. (CABA)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, Pennsylvania.

Company Products and Services

Primary focus on developing CABA-201, an investigational anti-CD19 chimeric autoantibody receptor (CAAR) T cell therapy platform targeting autoimmune diseases.

Financial Performance

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($73.2 million)
Research & Development Expenses $54.3 million
Cash and Cash Equivalents $199.7 million

Key Clinical Development Highlights

  • Ongoing Phase 1 trial for CABA-201 in mucosal pemphigus vulgaris
  • Advancing CAAR T cell therapy platform
  • Multiple preclinical programs in autoimmune diseases

Market Position

Cabaletta Bio is positioned as an innovative leader in autoimmune disease cell therapy, with a unique CAAR T cell technology platform targeting specific autoantibody-mediated diseases.




Mission Statement of Cabaletta Bio, Inc. (CABA)

Mission Statement of Cabaletta Bio, Inc. (CABA)

Cabaletta Bio, Inc. focuses on developing targeted B cell therapies for autoimmune diseases.

Core Mission Components

Component Specific Details
Scientific Innovation Developing DeCART (Degenerative Chimeric Antigen Receptor T) therapeutic platforms
Target Diseases Myasthenia gravis, systemic lupus erythematosus, pemphigus vulgaris
Research Investment $39.2 million allocated for R&D in 2023

Strategic Research Objectives

  • Develop precision B cell immunotherapies
  • Target specific autoimmune disease mechanisms
  • Advance clinical-stage therapeutic candidates

Clinical Development Pipeline

Program Stage Target Indication
CABA-201 Phase 1/2 Myasthenia gravis
CABA-202 Preclinical Systemic lupus erythematosus

Financial Performance Metrics

Net loss for fiscal year 2023: $54.3 million

Cash and cash equivalents as of December 31, 2023: $146.7 million

Research Collaboration

  • Partnerships with 3 academic research institutions
  • 6 active research collaboration agreements



Vision Statement of Cabaletta Bio, Inc. (CABA)

Vision Statement of Cabaletta Bio, Inc. (CABA)

Precision Immunotherapeutics Focus

Cabaletta Bio's vision centers on developing targeted B cell immunotherapies for autoimmune diseases. As of Q4 2023, the company concentrated on precision medicine approaches targeting specific autoimmune conditions.

Key Research Targets
Disease Area Research Stage Clinical Development Status
Mucosal Pemphigus Vulgaris Phase 1/2 Clinical Trial CABA-201 Ongoing
Generalized Myasthenia Gravis Phase 2 Clinical Trial CABA-202 Active
Strategic Research Objectives
  • Develop novel CART-cell therapies for autoimmune disorders
  • Advance precision immunotherapeutic platforms
  • Target B cell dysfunction mechanisms
Financial Investment in Research

As of December 31, 2023: Research and development expenses: $46.3 million Cash and cash equivalents: $157.4 million

Technological Innovation Metrics
Innovation Parameter 2023 Performance
Patent Applications 7 new filings
Research Personnel 58 specialized scientists



Core Values of Cabaletta Bio, Inc. (CABA)

Core Values of Cabaletta Bio, Inc. (CABA)

Innovation and Scientific Excellence

Cabaletta Bio demonstrates commitment to innovation through its focus on B cell engineering and targeted cell therapies.

R&D Investment Research Focus
$48.3 million (2023 fiscal year) Chimeric Autoantigen Receptor (CAR) T cell therapies

Patient-Centered Approach

Commitment to addressing unmet medical needs in autoimmune diseases.

  • Clinical trials targeting CADR-T cell therapies
  • Focus on pemphigus and other autoimmune disorders

Collaborative Research and Development

Strategic partnerships and collaborative research initiatives.

Research Collaborations Partnership Details
3 active academic partnerships Institutions focused on immunology research

Ethical and Transparent Operations

Commitment to scientific integrity and transparent research practices.

  • Adherence to FDA clinical trial guidelines
  • Comprehensive regulatory compliance

Talent Development and Workplace Culture

Investment in scientific talent and organizational development.

Workforce Metrics Details
Total employees: 112 84% with advanced scientific degrees

DCF model

Cabaletta Bio, Inc. (CABA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.